Juni 2022: Ngemva kwemigqa emibili noma ngaphezulu yokwelashwa kwe-systemic, i-FDA yaklomelisa i-tisagenlecleucel (Kymriah, Novartis Pharmaceuticals Corporation) yagunyaza ngokushesha iziguli ezikhulile ezine-lymphoma ebuyelelwe emuva noma e-refractory follicular (FL).T..